Abstract
In This Issue...
Metabolic diseases affect millions of people worldwide. Thousands of metabolic
diseases have been identified in humans, yet just a handful of these diseases
account for the vast majority of the morbidity and mortality. The World Health
Organization (WHO) estimates that type 2 diabetes affects 135 million people
worldwide and that 300 million people meet the criteria for obesity.
Dyslipidemia is another major metabolic disorder, affecting approximately 300
million people in the United States, Japan, and Western Europe.
Because these three disorders--type 2 diabetes, obesity, and dyslipidemia--are
highly prevalent and lead to significant morbidity and mortality, they are the
main focus of this report. We also discuss several metabolic disorders that
are less severe but account for significant morbidity. These disorders include
"metabolic syndrome" (which comprises several conditions), polycystic ovarian
syndrome (PCOS), and non-alcoholic steatohepatitis (NASH). (We do not discuss
hypertension, a common feature of metabolic syndrome, in this report because
it is multifactorial in origin and not generally considered a metabolic
disorder.)
Table of Contents
Executive Summary
- Which companies are the major players in the metabolic disease market?
- Which companies are the emerging players developing promising treatments
for metabolic diseases?
- What is the commercial outlook for the metabolic disease market?
Chapter 1. Background of a Worldwide Epidemic
Chapter 2. Overview of Metabolic Diseases
- Type 2 Diabetes
- Obesity
- Dyslipidemia
- Metabolic Syndrome
- Non-Alcoholic Steatohepatitis
- Polycystic Ovarian Syndrome
Chapter 3. Current and Emerging Treatments for Metabolic Diseases
- Drugs Targeting Type 2 Diabetes
- Insulin
- Inhaled Insulin
- Oral Insulin
- Sulfonylurea Drugs
- Meglitinides
- Biguanides
- Alpha-Glucosidase Inhibitors
- PPAR Agonists (Thiazolidinediones)
- Amylin Analogues
- Incretin Mimetics
- DPP-IV Inhibitors
- SGLT2 Inhibitors
- 11-Beta-HSD Type 1 Inhibitors
- Beta-3 Adrenergic Agonists
- Drugs Targeting Obesity
- Noradrenergic Anorectic Agents
- Serotonin-Norepinephrine Reuptake Inhibitors. .
- Lipase Inhibitors .
- Melanin-Concentrating Hormone Receptor Antagonists .
- Cannabinoid Antagonists
- Neuropeptide Y Agonists
- Drugs Targeting Dyslipidemia
- Statins (HMG-CoA Reductase Inhibitors) .
- Fibric Acids
- Bile Acid Sequestrants
- Nicotinic Acid
- Cholesterol Absorption Inhibitors .
- Cholesteryl Ester Transferase Protein Inhibitors.
- Squalene Synthase Inhibitors
- Microsomal Triglyceride Transfer Protein Inhibitors
- Acyl-CoA:Cholesterol Acyltransferase Inhibitors
Chapter 4. Company Profiles
- Abbott Laboratories
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- Alizyme
- Amgen.
- Amylin Pharmaceuticals
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- AstraZeneca
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- Bristol-Myers Squibb
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- Eli Lilly
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- GlaxoSmithKline
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- Isis Pharmaceuticals. .
- Ligand Pharmaceuticals .
- Merck & Co..
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- Metabolex
- Novartis
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- Novo Nordisk
- Currently Marketed Drugs for Metabolic Disorders
- Pfizer
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- Roche
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- Sanofi-Aventis
- Currently Marketed Drugs for Metabolic Disorders
- Drugs in Development
- Schering-Plough
- Currently Marketed Drugs for Metabolic Disorders
Chapter 5. Outlook for Metabolic Disease Therapeutics
Bibliography
医薬品
その他のカテゴリ
FAQ